2. Search Result
Search Result
Results for "

ischemic+heart

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

4

Biochemical Assay Reagents

2

Peptides

4

Natural
Products

2

Isotope-Labeled Compounds

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0203A
    Nebivolol hydrochloride
    3 Publications Verification

    R 065824 hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
    Nebivolol hydrochloride
  • HY-B0203
    Nebivolol
    3 Publications Verification

    R 065824

    		 Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Nebivolol (R 065824) is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
    Nebivolol
  • HY-W017540
    Cyclocreatine
    1 Publications Verification

    		 ATP Synthase Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .
    Cyclocreatine
  • HY-113110
    Cysteinylglycine

    L-Cysteinylglycine; Cys-Gly; H-Cys-Gly-OH

    		 Endogenous Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis Cardiovascular Disease Cancer
    Cysteinylglycine (L-Cysteinylglycine; Cys-Gly) is a dipeptide formed by the peptide bond linkage between cysteine (Cysteine) and glycine (Glycine). Cysteinylglycine is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine reduces ferric iron to ferrous iron, drives the redox cycle of iron, generates reactive oxygen species (ROS), stimulates oxidative reactions, induces lipid peroxidation of human plasma LDL lipoproteins, and causes oxidative damage to DNA bases. Cysteinylglycine can be used as a biomarker to evaluate ischemic heart disease, breast cancer and other conditions .
    Cysteinylglycine
  • HY-101327A
    Xamoterol hemifumarate

    Corwin hemifumarate; ICI 118587 hemifumarate

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease Metabolic Disease
    Xamoterol (Corwin; ICI 118587) hemifumarate is an orally active and selective β1-adrenoceptor partial agonist. Xamoterol hemifumarate acts as agonist at low sympathetic tone, antagonist at high sympathetic tone, with context-dependent cardiovascular effects including modulated heart rate, blood pressure, and cardiac output. Xamoterol hemifumarate can be used for the research of heart failure, postural hypotension, and ischemic heart disease .
    Xamoterol hemifumarate
  • HY-168894
    CT-1

    		Ferroptosis JAK STAT p38 MAPK AMPK GSK-3 Apoptosis HSP TNF Receptor Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    CT-1 is a secreted protein belonging to the IL-6 cytokine family. Overexpression of CT-1 enhances cell proliferation, migration and angiogenesis via the ADMA/DDAH pathway. CT-1 inhibits the growth of triple-negative breast cancer cells by simultaneously inducing Ferroptosis in N2-type tumor-associated neutrophils and cancer cells. CT-1 activates the Jak/STAT-3, p42/p44 MAPK and AMPK pathways, and inhibits GSK-3β activity through phosphorylation to induce cardiomyocyte hypertrophy. CT-1 enhances the viability of cardiomyocytes and neurons, reduces cell Apoptosis, induces the expression of heat shock proteins (HSP) and BNP, and inhibits TNF levels. CT-1 exerts anti-tumor activity in mouse models of triple-negative breast cancer. CT-1 improves cognitive impairment in mice. CT-1 is applicable to the research of ischemic heart disease, triple-negative breast cancer, myocardial hypertrophy, Parkinson's disease, hypertensive heart disease, myocardial infarction, acute Chagas cardiomyopathy, high-fat diet-induced cognitive impairment and diabetes-related cognitive impairment .
    CT-1
  • HY-107335
    Aplodan

    Creatinol O-phosphate; Creatinol phosphate; Creatinolfosfate

    		 Biochemical Assay Reagents Cardiovascular Disease
    Aplodan (Creatinol O-phosphate) is an antiischemic and antiarrhythmic agent. Aplodan has a protective action on cell membrane. Aplodan has the potential for the research of ischemic heart or acute myocardial infarction .
    Aplodan
  • HY-W329357
    15:0 Lyso PC
    1 Publications Verification

    		 Endogenous Metabolite Cardiovascular Disease
    15:0 Lyso PC is a lysophosphatidylcholine (Lyso PC), a product of phospholipase A2 (PLA2) hydrolysis of phosphatidylcholine (PC) and is involved in cell membrane remodeling and inflammatory signaling. 15:0 Lyso PC demonstrates significant lipid metabolism disturbances in the serum with ischemic heart disease (IHD) and ischemic cardiomyopathy (ICM). 15:0 Lyso PC can be used as a lipid biomarker for cardiovascular disease .
    15:0 Lyso PC
  • HY-N16650
    Bisadinrone A

    		Lactate Dehydrogenase Cardiovascular Disease
    Bisadinrone A is a sesquiterpene found in Curcuma longa. Bisadinrone A can inhibit LDH release and shows significant anti-myocardial ischemia-reperfusion injury activity. Bisadinrone A can be used for the research of cardiovascular disease, such as ischemic heart disease .
    Bisadinrone A
  • HY-113110A
    Cysteinylglycine TFA

    L-Cysteinylglycine TFA; Cys-Gly TFA; H-Cys-Gly-OH TFA

    		 Endogenous Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis Cardiovascular Disease Cancer
    Cysteinylglycine (L-Cysteinylglycine; Cys-Gly) TFA is a dipeptide formed by the peptide bond connection of cysteine and glycine. Cysteinylglycine TFA is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine TFA can reduce trivalent iron to divalent iron, driving the redox cycle of iron, generating reactive oxygen species (ROS), stimulating oxidative reactions, inducing lipid peroxidation in human plasma LDL lipoproteins, and causing oxidative damage to DNA base. Cysteinylglycine TFA can be used as a biomarker to assess ischemic heart disease and breast cancer, etc [1][2][3][4].
    Cysteinylglycine TFA
  • HY-101327
    Xamoterol

    Corwin; ICI 118587

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease Metabolic Disease
    Xamoterol (Corwin; ICI 118587) is an orally active and selective β1-adrenoceptor partial agonist. Xamoterol acts as agonist at low sympathetic tone, antagonist at high sympathetic tone, with context-dependent cardiovascular effects including modulated heart rate, blood pressure, and cardiac output. Xamoterol can be used for the research of heart failure, postural hypotension, and ischemic heart disease .
    Xamoterol
  • HY-113110R
    Cysteinylglycine (Standard)

    L-Cysteinylglycine (Standard); Cys-Gly (Standard); H-Cys-Gly-OH (Standard)

    		 Reference Standards Endogenous Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis Cardiovascular Disease Cancer
    Cysteinylglycine (Standard) is the analytical standard of Cysteinylglycine. This product is intended for research and analytical applications. Cysteinylglycine is a dipeptide formed by the peptide bond linkage between cysteine (Cysteine) and glycine (Glycine). Cysteinylglycine is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine reduces ferric iron to ferrous iron, drives the redox cycle of iron, generates reactive oxygen species (ROS), stimulates oxidative reactions, induces lipid peroxidation of human plasma LDL lipoproteins, and causes oxidative damage to DNA bases. Cysteinylglycine can be used as a biomarker to evaluate ischemic heart disease, breast cancer and other conditions .
    Cysteinylglycine (Standard)
  • HY-W017540R
    Cyclocreatine (Standard)

    		Reference Standards ATP Synthase Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .
    Cyclocreatine (Standard)
  • HY-172687A
    DSPE-PEG3400-CSTSMLKAC

    		Liposome Cardiovascular Disease
    DSPE-PEG3400-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG3400-CSTSMLKAC can be used for drug delivery .
    DSPE-PEG3400-CSTSMLKAC
  • HY-172688
    DSPE-PEG5000-CSTSMLKAC

    		Liposome Cardiovascular Disease
    DSPE-PEG5000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG5000-CSTSMLKAC can be used for drug delivery .
    DSPE-PEG5000-CSTSMLKAC
  • HY-123721
    Tiracizine hydrochloride

    AWD-19-166; GS 015

    		 Endogenous Metabolite Cardiovascular Disease
    Tiracizine hydrochloride (AWD-19-166) is a Class I antiarrhythmic drug with activity that reduces myocardial contractile function. Tiracizine hydrochloride was studied in patients with ischemic heart disease, showing its effects on the myocardium. Tiracizine hydrochloride reduces myocardial contractility and may have potential use in the management of heart disease .
    Tiracizine hydrochloride
  • HY-161703
    2-Hydroxy-3′-O-methyladenosine

    		Adenosine Deaminase Cardiovascular Disease
    2-Hydroxy-3′-O-methyladenosine is a synthetic intermediate product that can be used in the research of ischemic heart disease, cerebrovascular disease, kidney disease, inflammatory allergies and other diseases. 2-phenylamino-N6,2'-O-dimethyladenosine produced from 2-Hydroxy-3′-O-methyladenosine is an inhibitor of adenosine deaminase with a Ki of 13 nM .
    2-Hydroxy-3′-O-methyladenosine
  • HY-176333
    Nebivolol O-β-D-glucuronide

    		Adrenergic Receptor Cardiovascular Disease Endocrinology
    Nebivolol O-β-D-glucuronide is a derivative of Nebivolol (HY-B0203). Nebivolol is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
    Nebivolol O-β-D-glucuronide
  • HY-B0203AR
    Nebivolol hydrochloride (Standard)

    R 065824 hydrochloride (Standard)

    		 Reference Standards Adrenergic Receptor Cardiovascular Disease Endocrinology
    Nebivolol (hydrochloride) (Standard) is the analytical standard of Nebivolol (hydrochloride). This product is intended for research and analytical applications. Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
    Nebivolol hydrochloride (Standard)
  • HY-146925S
    15:0 Lyso PC-d5

    		Isotope-Labeled Compounds Endogenous Metabolite Cardiovascular Disease
    15:0 Lyso PC-d5 is deuterium labeled 15:0 Lyso PC (HY-W329357). 15:0 Lyso PC is a lysophosphatidylcholine (Lyso PC), a product of phospholipase A2 (PLA2) hydrolysis of phosphatidylcholine (PC) and is involved in cell membrane remodeling and inflammatory signaling. 15:0 Lyso PC demonstrates significant lipid metabolism disturbances in the serum of patients with ischemic heart disease (IHD) and ischemic cardiomyopathy (ICM). 15:0 Lyso PC can be used as a lipid biomarker for cardiovascular disease.
    15:0 Lyso PC-d5
  • HY-116295
    MRS2690

    		P2Y Receptor p38 MAPK Calcium Channel Cardiovascular Disease
    MRS2690 is a selective P2Y14 receptor agonist. MRS2690 inhibits adenylyl cyclase activity, thereby reducing intracellular cAMP levels and mediating concentration-dependent vasoconstriction of porcine coronary arteries. MRS2690 induces intracellular calcium mobilization, activates P38 and stimulates [ 35S]GTPγS binding to RBL-2H3 cell membranes. MRS2690 enhances antigen (NP-BSA)-, C3a-induced β-hexosaminidase (β-Hex) release. MRS2690can be used for ischemic heart disease .
    MRS2690
  • HY-116295A
    MRS2690 disodium

    		P2Y Receptor p38 MAPK Calcium Channel Cardiovascular Disease
    MRS2690 disodium is a selective P2Y14 receptor agonist. MRS2690 disodium inhibits adenylyl cyclase activity, thereby reducing intracellular cAMP levels and mediating concentration-dependent vasoconstriction of porcine coronary arteries. MRS2690 disodium induces intracellular calcium mobilization, activates P38 and stimulates [ 35S]GTPγS binding to RBL-2H3 cell membranes. MRS2690 enhances antigen (NP-BSA)-, C3a-induced β-hexosaminidase (β-Hex) release. MRS2690 disodium can be used for ischemic heart disease .
    MRS2690 disodium
  • HY-W017540S
    Cyclocreatine-13C3

    		Isotope-Labeled Compounds ATP Synthase Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Cyclocreatine- 13C3 is the 13C-labeled Cyclocreatine (HY-W017540). Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .
    Cyclocreatine-13C3
  • HY-172686
    DSPE-PEG1000-CSTSMLKAC

    		Liposome Cardiovascular Disease
    DSPE-PEG1000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG1000-CSTSMLKAC can be used for drug delivery .
    DSPE-PEG1000-CSTSMLKAC
  • HY-107335R
    Aplodan (Standard)

    Creatinol O-phosphate (Standard); Creatinol phosphate (Standard); Creatinolfosfate (Standard)

    		 Biochemical Assay Reagents Reference Standards Cardiovascular Disease
    Aplodan (Standard) (Creatinol O-phosphate (Standard)) is the analytical standard of Aplodan (HY-107335). This product is intended for research and analytical applications. Aplodan (Creatinol O-phosphate) is an antiischemic and antiarrhythmic agent. Aplodan has a protective action on cell membrane. Aplodan has the potential for the research of ischemic heart or acute myocardial infarction .
    Aplodan (Standard)
  • HY-123059A
    (2S,3S)-Zenidolol hydrochloride

    (2S,3S)-ICI-118551 hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease
    (2S,3S)-Zenidolol ((2S,3S)-ICI-118551) hydrochloride is a β2-adrenergic receptor (β2AR) antagonist with pKi values for β1AR and β2AR of 7.51 and 9.27 respectively. (2S,3S)-Zenidolol hydrochloride can be used in the research of heart failure, ischemic heart disease and hypertension .
    (2S,3S)-Zenidolol hydrochloride
  • HY-101327AR
    Xamoterol hemifumarate (Standard)

    Corwin hemifumarate (Standard); ICI 118587 hemifumarate (Standard)

    		 Adrenergic Receptor Reference Standards Cardiovascular Disease Neurological Disease Metabolic Disease
    Xamoterol hemifumarate (Standard) is the analytical standard of Xamoterol hemifumarate (HY-101327A). This product is intended for research and analytical applications. Xamoterol (Corwin; ICI 118587) hemifumarate is an orally active and selective β1-adrenoceptor partial agonist. Xamoterol hemifumarate acts as agonist at low sympathetic tone, antagonist at high sympathetic tone, with context-dependent cardiovascular effects including modulated heart rate, blood pressure, and cardiac output. Xamoterol hemifumarate can be used for the research of heart failure, postural hypotension, and ischemic heart disease .
    Xamoterol hemifumarate (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: